10-Q/A: Ainos Inc. Reports Q3 2023 Results: Revenue Declines Amid Shift to New Product Focus

Ainos Inc. reported a significant decrease in revenue for the third quarter of 2023, primarily due to reduced sales of COVID-19 test kits, while the company focuses on new product development and commercialization.

Summary

• Ainos Inc. experienced a substantial decrease in revenue, dropping from $1,757,774 in Q3 2022 to $24,489 in Q3 2023, mainly due to a decline in COVID-19 test kit sales.
• The company's gross profit turned into a loss of $63,384 in Q3 2023, compared to a profit of $581,742 in Q3 2022, due to decreased sales and inventory write-downs.
• Operating expenses decreased from $8,404,013 in Q3 2022 to $2,612,282 in Q3 2023, primarily due to a reduction in share-based compensation.
• The net loss for Q3 2023 was $2,975,846, a significant improvement from the $7,821,756 loss in Q3 2022.
• For the nine months ended September 30, 2023, revenue was $102,208, a sharp decrease from $2,481,602 in the same period of 2022.
• The net loss for the first nine months of 2023 was $7,846,048, compared to $11,875,682 for the same period in 2022.
• The company secured $3 million in convertible note financing in March 2023 and $2 million from a senior secured convertible note in September 2023.
• Ainos is shifting its focus to commercializing VELDONA Pet supplements and developing its AI Nose technology for point-of-care testing.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has reduced its losses and secured new financing, the significant revenue decline and going concern uncertainty temper any positive outlook. The shift to new products is promising but carries execution risk.

Positives

• The net loss significantly decreased in both Q3 2023 and the first nine months of 2023 compared to the same periods in 2022.
• Operating expenses were substantially reduced, primarily due to lower share-based compensation.
• The company secured $5 million in financing through convertible notes.
• Ainos is actively diversifying its revenue streams by launching VELDONA Pet supplements.
• The company is progressing with the development of its AI Nose technology for point-of-care testing.

Negatives

• Revenue from COVID-19 test kits declined dramatically, impacting overall revenue.
• The company experienced a gross loss in Q3 2023 due to decreased sales and inventory write-downs.
• The company has an accumulated deficit of $31,961,654 as of September 30, 2023.
• There is substantial doubt about the company's ability to continue as a going concern for at least one year.
• The company is dependent on additional financing to fund its operations.

Risks

• The company's ability to meet its obligations is dependent on generating sufficient cash flows from operations and future financing transactions.
• There is no assurance that the company will be able to obtain additional financing on acceptable terms or at all.
• The company has incurred net operating losses in every year since inception and expects to incur additional losses and negative operating cash flows for at least the next twelve months.
• All of the company's assets, subject to certain exceptions, have been pledged as security for the Lind Note, and a default could lead to foreclosure.
• The company operates in an industry characterized by extensive patent litigation, which could be costly and time-consuming.

Future Outlook

The company anticipates that cash reserves, business revenues, and potential debt financing will fund operations over the next twelve months. Ainos expects to generate sales revenue from VELDONA Pet in the near term and is prioritizing the commercialization of Ainos Flora and out-licensing of VELDONA human drug candidates.

Management Comments

• The company is prioritizing sales and marketing of VELDONA Pet, commercializing Ainos Flora, and pursuing out-licensing of VELDONA human drug candidates.
• The company believes that post COVID-19, consumers have become increasingly familiar with at-home tests and may seek additional at-home tests to manage other infections.
• The company is expanding capacity with its contract manufacturers to meet anticipated demand for VELDONA Pet.

Industry Context

The decline in COVID-19 test kit sales reflects a broader trend in the healthcare industry as the pandemic's impact wanes. Ainos's pivot to point-of-care testing and pet supplements aligns with the growing demand for convenient health solutions and the expanding pet care market. The company's focus on AI-powered diagnostics also positions it within the emerging trend of digital health technologies.

Comparison to Industry Standards

• The dramatic decline in COVID-19 test kit revenue is consistent with the industry-wide trend as the pandemic's impact diminishes, affecting companies like Abbott and Quidel.
• Ainos's shift to point-of-care testing aligns with the broader industry trend of decentralized diagnostics, similar to companies like Cue Health and Lucira Health.
• The development of VELDONA Pet supplements places Ainos in the growing pet health and wellness market, competing with established players like Zoetis and Elanco.
• The company's focus on AI-powered diagnostics is comparable to other companies leveraging artificial intelligence in healthcare, such as Butterfly Network and Paige.
• The financial results show a significant decrease in revenue and a net loss, which is not uncommon for early-stage biotech companies focused on R&D and product development, similar to companies like Novavax and Moderna in their early stages.

Related Party Transactions

• The company had various related party transactions, including sales of COVID-19 test kits to affiliates of ASE Test Inc., and manufacturing service agreements with TCNT.
• The company issued 61,157 shares of common stock to a director, Ting-Chuan Lee, for the acquisition of a motor vehicle.
• The company engaged Ms. Chien-Hsuan Huang, the spouse of a board member, as a medical device development consultant.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers of COVID-19 test kits may need to seek alternative suppliers.
• Suppliers may face uncertainty due to the company's financial situation.
• Creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company plans to expand capacity with its contract manufacturers to meet anticipated demand for VELDONA Pet.
• The company will continue to develop its VOC POCT and VELDONA drug candidates and increase the pace of clinical trials.
• The company will allocate sales and marketing efforts for VELDONA Pet.
• The company will explore commercial opportunities for VELDONA Pet in other Asian regions and the U.S.A.

Key Dates

Keywords

COVID-19 test kits, VELDONA Pet, AI Nose technology, point-of-care testing, convertible notes, financial results, revenue decline, operating loss, share-based compensation, clinical trials